211 related articles for article (PubMed ID: 20567995)
21. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
22. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
23. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
[TBL] [Abstract][Full Text] [Related]
24. The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.
Thomas A; Perry T; Berhane S; Oldreive C; Zlatanou A; Williams LR; Weston VJ; Stankovic T; Kearns P; Pors K; Grand RJ; Stewart GS
Oncogene; 2015 Jun; 34(25):3336-48. PubMed ID: 25132271
[TBL] [Abstract][Full Text] [Related]
25. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
Wang N; Zhu M; Tsao SW; Man K; Zhang Z; Feng Y
Mol Cancer; 2013 Oct; 12(1):119. PubMed ID: 24103454
[TBL] [Abstract][Full Text] [Related]
26. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
27. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
28. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
29. CtIP promotes G2/M arrest in etoposide-treated HCT116 cells in a p53-independent manner.
Chen H; Shan J; Chen D; Wang R; Qi W; Wang H; Ke Y; Liu W; Zeng X
J Cell Physiol; 2019 Jul; 234(7):11871-11881. PubMed ID: 30478995
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of p53 by adenovirus type 12 E1B-55K deregulates cell cycle control and sensitizes tumor cells to genotoxic agents.
Li Q; Zhao LY; Zheng Z; Yang H; Santiago A; Liao D
J Virol; 2011 Aug; 85(16):7976-88. PubMed ID: 21680522
[TBL] [Abstract][Full Text] [Related]
32. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
[TBL] [Abstract][Full Text] [Related]
34. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
36. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
37. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
38. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
39. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
[TBL] [Abstract][Full Text] [Related]
40. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]